Probiotic and prebiotic use in patients with inflammatory bowel disease: A case-control study

Inflammatory Bowel Diseases

Volumn 16, Issue 12, 2010, Pages 2099-2108

  Hedin, Charlotte R H ^a   Mullard, Miriam ^a   Sharratt, Elizabeth ^a   Jansen, Clare ^a   Sanderson, Jeremy D ^a   Shirlaw, Penelope ^b   Howe, Leslie C ^b   Djemal, Serpil ^c   Stagg, Andrew J ^d   Lindsay, James O ^d   Whelan, Kevin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CAM; inflammatory bowel disease; prebiotic; probiotic; questionnaire

Indexed keywords

ACIDOPHILUS; ACTIMEL; ACTIVIA; PREBIOTIC AGENT; PROBIOTIC AGENT; STEROID; UNCLASSIFIED DRUG; VSL3; YAKULT;

ADOLESCENT; ADVERTIZING; ALTERNATIVE MEDICINE; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DRUG USE; ENTERITIS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH; HEALTH CARE PERSONNEL; HUMAN; INFORMATION; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREBIOTICS; PROBIOTICS; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649620656     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21286     Document Type: Article

References (73)

1. Drossman DA, Patrick DL, Mitchell CM, et al. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci. 1989; 34: 1379-1386.
2. Love JR, Irvine EJ, Fedorak RN,. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992; 14: 15-19.
3. Patrick DL, Deyo RA,. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989; 27: S217-S232.
4. Sirois FM,. Provider-based complementary and alternative medicine use among three chronic illness groups: associations with psychosocial factors and concurrent use of conventional health-care services. Complement Ther Med. 2008; 16: 73-80.
5. Kong SC, Hurlstone DP, Pocock CY, et al. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005; 39: 138-141.
6. NCCAM. What is complementary and alternative medicine? National Center for Complementary Medicine Website. Available at: Accessed October 24th 2009.
7. WHO/FAO. Guidelines for the evaluation of probiotics in food. Rome/Geneva; 2002.
8. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119: 305-309.
9. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003; 124: 1202-1209.
10. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004; 53: 108-114.
11. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005; 22: 721-728.
12. Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005; 40: 43-51.
13. Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004; 47: 876-884.
14. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007; 50: 2075-2082.
15. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008; 2: 24-62.
16. Malchow HA,. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997; 25: 653-658.
17. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006; 55: 842-847.
18. Gibson GR, Roberfroid MB,. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125: 1401-1412.
19. Langlands SJ, Hopkins MJ, Coleman N, et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut. 2004; 53: 1610-1616.
20. Hoentjen F, Welling GW, Harmsen HJ, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis. 2005; 11: 977-985.
21. Videla S, Vilaseca J, Antolin M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol. 2001; 96: 1486-1493.
22. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002; 45: 621-627.
23. Casellas F, Borruel N, Torrejon A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007; 25: 1061-1067.
24. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 2006; 55: 348-355.
25. Barnes PM, Powell-Griner E, McFann K, et al. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004; 1-19.
26. Barnes PM, Bloom B, Nahin RL,. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008; 1-23.
27. Nahin RL, Barnes PM, Stussman BJ, et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report. 2009; 1-24.
28. Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res. 1996; 40: 503-509.
29. Hilsden RJ, Verhoef MJ, Best A, et al. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003; 98: 1563-1568.
30. Hilsden RJ, Scott CM, Verhoef MJ,. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol. 1998; 93: 697-701.
31. Hilsden RJ, Meddings JB, Verhoef MJ,. Complementary and alternative medicine use by patients with inflammatory bowel disease: an Internet survey. Can J Gastroenterol. 1999; 13: 327-332.
32. Moody GA, Eaden JA, Bhakta P, et al. The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health. 1998; 112: 269-271.
33. Rawsthorne P, Shanahan F, Cronin NC, et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 1298-1303.
34. Giese LA,. A study of alternative health care use for gastrointestinal disorders. Gastroenterol Nurs. 2000; 23: 19-27.
35. Langmead L, Chitnis M, Rampton DS,. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis. 2002; 8: 174-179.
36. Quattropani C, Ausfeld B, Straumann A, et al. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol. 2003; 38: 277-282.
37. Leong RW, Lawrance IC, Ching JY, et al. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci. 2004; 49: 1672-1676.
38. Ganguli SC, Cawdron R, Irvine EJ,. Alternative medicine use by Canadian ambulatory gastroenterology patients: secular trend or epidemic? Am J Gastroenterol. 2004; 99: 319-326.
39. Burgmann T, Rawsthorne P, Bernstein CN,. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol. 2004; 99: 889-893.
40. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005; 11: 287-295.
41. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med. 2007; 15: 30-37.
42. Li FX, Verhoef MJ, Best A, et al. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol. 2005; 19: 567-573.
43. Joos S, Rosemann T, Szecsenyi J, et al. Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006; 6: 19.
44. D'Inca R, Garribba AT, Vettorato MG, et al. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis. 2007; 39: 524-529.
45. Garcia-Planella E, Marin L, Domenech E, et al. [Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease]. Med Clin (Barc). 2007; 128: 45-48.
46. Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol. 2002; 97: 382-388.
47. Schafer T,. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol. 2004; 93: S5-10.
48. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009; MR000008.
49. Kelley K, Clark B, Brown V, et al. Good practice in the conduct and reporting of survey research. Int J Qual Health Care. 2003; 15: 261-266.
50. Bernstein CN,. Complementary and alternative medicine use by patients with inflammatory bowel disease: are Canadian physicians failing with conventional therapy, or not? Can J Gastroenterol. 2004; 18: 47-48.
51. Sitzia J, Wood N,. Response rate in patient satisfaction research: an analysis of 210 published studies. Int J Qual Health Care. 1998; 10: 311-317.
52. Tonder van E, Herselman MG, Visser J,. The prevalence of dietary-related complementary and alternative therapies and their perceived usefulness among cancer patients. J Hum Nutr Diet. 2009: 528-535.
53. Wallston KA, Stein MJ, Smith CA,. Form C of the MHLC scales: a condition-specific measure of locus of control. J Pers Assess. 1994; 63: 534-553.
54. Wallston KA, Wallston BS, DeVellis R,. Development of the Multidimensional Health Locus of Control (MHLC) Scales. Health Educ Monogr. 1978; 6: 160-170.
55. Talbot F, Nouwen A, Gauthier J,. Is health locus of control a 3-factor or a 2-factor construct? J Clin Psychol. 1996; 52: 559-568.
56. Wallston KA,. The validity of the multidimensional health locus of control scales. J Health Psychol. 2005; 10: 623-631.
57. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (suppl 1): i16-i35.
58. Landström E, Hursti UK, Becker W, et al. Use of functional foods among Swedish consumers is related to health-consciousness and perceived effect. Br J Nutr. 2007; 98: 1058-1069.
59. de JN, Ocke MC, Branderhorst HA, et al. Demographic and lifestyle characteristics of functional food consumers and dietary supplement users. Br J Nutr. 2003; 89: 273-281
60. Mullie P, Guelinckx I, Clarys P, et al. Cultural, socioeconomic and nutritional determinants of functional food consumption patterns. Eur J Clin Nutr. 2009; 63: 1290-1296.
61. Tippens K, Marsman K, Zwickey H,. Is prayer CAM? J Altern Complement Med. 2009; 15: 435-438.
62. Boye B, Jahnsen J, Mokleby K, et al. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Inflamm Bowel Dis. 2008; 14: 680-686.
63. Hedin C, Whelan K, Lindsay JO,. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. 2007; 66: 307-315.
64. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004; 10: I126-I131.
65. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology. 2000; 118: G4179.
66. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009; 104: 437-443.
67. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008; 14: 662-668.
68. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997; 11: 853-858.
69. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53: 1617-1623.
70. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999; 354: 635-639.
71. Petersen PE, Yamamoto T,. Improving the oral health of older people: the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol. 2005; 33: 81-92.
72. Prendergast MJ, Beal JF, Williams SA,. The relationship between deprivation, ethnicity and dental health in 5-year-old children in Leeds, UK. Community Dent Health. 1997; 14: 18-21.
73. Borrell LN, Beck JD, Heiss G,. Socioeconomic disadvantage and periodontal disease: the Dental Atherosclerosis Risk in Communities study. Am J Public Health. 2006; 96: 332-339. (Pubitemid 43167134)